https://promontorytx.com/news daily 0.75 2025-12-22 https://promontorytx.com/news/promontory-therapeutics-announces-interim-efficacy-requirement-reached-on-phase-2-study-of-pt-112-monotherapy-in-patients-with-recurrent-thymoma monthly 0.5 2025-12-22 https://promontorytx.com/news/promontory-therapeutics-announces-successful-end-of-phase-2-meeting-with-us-fda-on-phase-3-registrational-study-design-for-pt-112-in-patients-with-metastatic-castration-resistant-prostate-cancer monthly 0.5 2025-05-20 https://promontorytx.com/news/cd7eacod4ol9nrmti1uhxe5bfzylwc monthly 0.5 2025-05-19 https://promontorytx.com/news/promontory-therapeutics-announces-presentation-on-clinical-immune-responses-to-pt-112-monotherapy-at-the-2025-aacr-annual-meeting monthly 0.5 2025-03-25 https://promontorytx.com/news/promontory-therapeutics-completes-enrollment-of-phase-2-trial-of-pt-112-in-late-line-patients-with-metastatic-castration-resistant-prostate-cancer monthly 0.5 2024-03-08 https://promontorytx.com/news/promontory-therapeutics-presents-data-on-molecular-mechanisms-of-pt-112s-immunogenic-effects monthly 0.5 2023-11-04 https://promontorytx.com/news/promontory-therapeutics-presents-data-on-the-molecular-effects-of-pt-112-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics monthly 0.5 2023-10-14 https://promontorytx.com/news/promontory-therapeutics-announces-early-phase-2-clinical-trial-data-from-the-national-cancer-institute-demonstrating-pt-112s-immune-activation-in-thymic-epithelial-tumors monthly 0.5 2023-10-05 https://promontorytx.com/news/promontory-therapeutics-selected-as-the-first-international-biotech-company-member-of-the-paris-saclay-cancer-cluster monthly 0.5 2023-09-29 https://promontorytx.com/news/t73be1sa7mz1kvhzs6sm9vg81mb2cn monthly 0.5 2023-11-07 https://promontorytx.com/news/promontory-therapeutics-expands-phase-2-trial-of-pt-112-in-metastatic-castrate-resistant-prostate-cancer-to-france monthly 0.5 2023-07-20 https://promontorytx.com/news/promontory-therapeutics-announces-preliminary-data-from-the-national-cancer-institute-phase-2-clinical-trial-of-pt-112-in-thymoma-and-thymic-carcinoma-at-2023-asco-annual-meeting monthly 0.5 2023-06-02 https://promontorytx.com/news/promontory-therapeutics-to-participate-in-business-development-strategies-panel-at-the-sachs-9th-annual-immuno-oncology-innovation-forum monthly 0.5 2023-05-31 https://promontorytx.com/news/promontory-therapeutics-presents-phase-2-trial-in-progress-for-pt-112-in-prostate-cancer-at-2023-asco-genitourinary-cancers-symposium monthly 0.5 2023-02-16 https://promontorytx.com/news/promontory-therapeutics-presents-safety-and-efficacy-data-of-pt-112-in-combination-with-pd-l1-inhibition-in-treatment-of-advanced-non-small-cell-lung-cancer-at-esmo-i-o-2022 monthly 0.5 2022-12-08 https://promontorytx.com/news/promontory-therapeutics-appoints-stan-musial-as-chief-financial-officer monthly 0.5 2022-11-28 https://promontorytx.com/news/promontory-therapeutics-presents-on-the-immunological-effects-of-pt-112-in-cancer-cell-mitochondria-at-sitc-2022 monthly 0.5 2022-11-11 https://promontorytx.com/news/promontory-therapeutics-awarded-cancer-immunology-solution-of-the-year-in-2022-biotech-breakthrough-awards-program monthly 0.5 2022-11-07 https://promontorytx.com/news/promontory-therapeutics-reports-pt-112s-effects-on-human-prostate-cancer-cell-mitochondria-at-the-34th-eortc-nci-aacr-symposium monthly 0.5 2022-10-26 https://promontorytx.com/news/promontory-therapeutics-receives-us-patent-for-therapeutic-applications-of-pt-112-as-an-immuno-modulatory-agent monthly 0.5 2022-10-20 https://promontorytx.com/news/promontory-therapeutics-appoints-two-experienced-executives-to-its-core-management-team monthly 0.5 2022-09-13 https://promontorytx.com/news/promontory-therapeutics-announces-peer-reviewed-publication-in-cancers-of-selective-effects-of-pt-112-in-cancer-cell-models-driven-by-mitochondrial-dysfunction monthly 0.5 2022-08-11 https://promontorytx.com/news/pxj0t413euc216bc1isoumjjea0b12 monthly 0.5 2022-06-20 https://promontorytx.com/news/promontory-therapeutics-announces-peer-reviewed-publication-of-first-in-human-clinical-trial-of-pt-112-in-the-lancets-eclinicalmedicine monthly 0.5 2022-06-08 https://promontorytx.com/news/promontory-therapeutics-appoints-johan-baeck-md-as-executive-vice-president-and-chief-medical-officer monthly 0.5 2022-05-23 https://promontorytx.com/news/phosplatin-therapeutics-adopts-new-corporate-name-as-promontory-therapeutics-inc monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-pt-112 monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-appoints-lorenzo-galluzzi-phd-a-pioneer-in-immunogenic-cell-death-research-to-scientific-advisory-board-gas6f monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-appoints-sebastian-guth-phd-to-board-of-directors-5c83b monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-37-million-series-a-financing-csbht monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-collaborates-with-the-national-cancer-institute-for-phase-2-proof-of-concept-study-of-pt-112-in-thymoma-and-thymic-carcinoma-4tbhw monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-reports-phase-1b-study-results-of-immunogenic-cell-death-inducer-pt-112-plus-pd-l1-inhibitor-avelumab-in-metastatic-prostate-cancer-at-asco-annual-meeting-tp3es monthly 0.5 2025-05-20 https://promontorytx.com/news/insights-into-a-new-anticancer-therapy-and-what-payers-should-know-dxrhg monthly 0.5 2025-05-20 https://promontorytx.com/news/ltio39lx1t0nve11j2lv0xzl5gkjs1-rrdsz monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-presents-phase-i-dose-escalation-data-of-pt-112-in-patients-with-relapsed-refractory-multiple-myeloma-at-ash-annual-meeting-ka667 monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-data-revealing-novel-mechanistic-attributes-for-pt-112-at-the-32nd-eortc-nci-aacr-virtual-symposium-yam4s monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-results-from-phase-1b-dose-escalation-study-of-pt-112-plus-avelumab-in-patients-with-solid-tumors-g8x42 monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-two-leadership-appointments-wmxr5 monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-completes-184-million-private-financing-round-f4xz3 monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-receives-notice-of-us-patent-issuance-for-pt-112-as-therapeutic-agent-for-treatment-of-bone-or-blood-cancers-j3tha monthly 0.5 2025-05-20 https://promontorytx.com/news/blog-post-title-one-3kmth-egwdd monthly 0.5 2025-05-20 https://promontorytx.com/news/blog-post-title-two-28j3a-ze5x7 monthly 0.5 2025-05-20 https://promontorytx.com/news/mcivg7xmx4pxat0qg4ie7xbjjph8at-g27k3 monthly 0.5 2025-05-20 https://promontorytx.com/news/placeholder-phosplatin-to-create-new-76tt6 monthly 0.5 2025-05-20 https://promontorytx.com/news/blog-post-title-four-xtgxb-r9rha monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-honored-at-the-european-society-of-medical-oncology-esmo-2018-annual-meeting-2axsf monthly 0.5 2025-05-20 https://promontorytx.com/news/blog-post-title-three-dw6hp-kmlk3 monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-collaboration-with-pfizer-and-merck-kgaa-darmstadt-germany-to-evaluate-combination-of-pt-112-and-avelumab-in-phase-i-ii-studies-nhep4 monthly 0.5 2025-05-20 https://promontorytx.com/news/sciclone-announces-progress-in-advancing-clinical-pipeline-for-china-pharmaceuticals-market-sdzbj monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-the-execution-of-regional-licensing-agreement-for-its-novel-therapeutic-agent-in-oncology-pt-112-m3pym monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-saddened-by-the-loss-of-rathindra-bose-inventor-of-phosphaplatins-46mhh monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-appoints-jos-jimeno-md-phd-as-chief-medical-officer-gtph7 monthly 0.5 2025-05-20 https://promontorytx.com/news/phosplatin-therapeutics-announces-first-patients-enrolled-in-phase-i-first-in-human-clinical-trial-in-solid-tumors-3pma8 monthly 0.5 2025-05-20 https://promontorytx.com/news/category/Press+Release monthly 0.5 https://promontorytx.com/home daily 1.0 2025-05-19 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/31cf50da-acff-4d5a-8522-9254478ebb6a/NEW_blue_background.jpg Home - Learn about our lead clinical drug candidate. PT-112 ⭢ https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748451522-BOAPJN2VPCCNU7F8GVWD/gray_background.jpg Home - How our agent induces an adaptive immune response. OUR SCIENCE ⭢ https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/fab89789-090b-4588-8734-1d385ed96745/NEW_green_background.jpg Home - Why Promontory is different from others. ABOUT US ⭢ https://promontorytx.com/non-clinical-research daily 0.75 2023-05-11 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748454893-Y1MS38H468EAKW29EVNA/45-min.png Non-Clinical Research Whole mouse imaging https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748454897-3V0MEY63MDOE6NWQRWW8/femur.jpg Non-Clinical Research High resolution mouse femur / tibia https://promontorytx.com/clinical-trials daily 0.75 2025-03-26 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/f029ea4f-850c-4132-aa7d-2e47a1c29594/Picture5.png Clinical Trials & Pipeline [2] https://promontorytx.com/publications-old daily 0.75 2025-05-20 https://promontorytx.com/key-milestones daily 0.75 2025-05-19 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466860-BV0FCMGGJ36KO7EO8LJF/ohio-university.jpg PT-112 Key Milestones - 2011 Promontory Therapeutics was founded (under the name Phosplatin Therapeutics) with seed funding and its discovery-stage license transaction with Ohio University for a family of compounds intended for development as anti-cancer agents. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/4d3f72e8-1e58-4c58-b1b0-4269537bcb3b/GettyImages-1363707600.jpg PT-112 Key Milestones - 2023 Promontory Therapeutics was named a Best Startup Nominee under the prestigious Prix Galien USA. The PT-112 Phase 2 study in mCRPC was expanded into France, led by the Gustave Roussy Paris, and became the first international member of the Paris Saclay Cancer Cluster. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466873-QD2PVE20VKF1TTCIUWZZ/gettyimages-1212821220-170667a.jpg PT-112 Key Milestones - 2014 Promontory launched its First-in-Human Phase I Clinical Trial of PT-112 in Solid Tumors. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466911-NQFNR3IL8346HLKP4H2L/IMG_6996.jpg PT-112 Key Milestones - 2020 Positive data from two phase I studies in metastatic castrate-resistant prostate cancer (mCRPC) patients were presented at the American Society of Cancer Oncology’s Genitourinary (ASCO GU) Symposium. Promontory announced the publication in OncoImmunology of in vitro and in vivo data demonstrating PT-112’s induction of immunogenic cell death (ICD). The Phase 2 study of PT-112 in mCRPC was launched late in the year, amidst the global Covid-19 pandemic. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466902-2IT1FWU783Q3582SPIW9/Ro+%26+Matthew+ESMO+Best+Poster.jpg PT-112 Key Milestones - 2018 PT-112 received FDA Orphan Drug Designation for use in thymoma and thymic carcinoma. The PT-112-101 Phase I study team was awarded with “Best Poster” honors across the full Developmental Therapeutics category at the European Society of Medical Oncology Annual Congress in Munich, Germany. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/ca5072fd-b086-4f17-9bda-c4ddc0d4a6e2/Biotech+Breakthrough+2022-Promontory.png PT-112 Key Milestones - 2022 Promontory Therapeutics received the 2022 “Cancer Immunology Solution of the Year” award in the second annual BioTech Breakthrough Awards program. The Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466906-SEMUPXHY14HFXKOM4PJQ/esmo2019.jpg PT-112 Key Milestones - 2019 Promontory gathered experts during the European Society of Medical Oncology Annual Congress to constitute its Clinical Advisory Group in prostate cancer. Promontory also presented at BIO CEO. https://promontorytx.com/contact-us daily 0.75 2022-04-28 https://promontorytx.com/leadership-1 daily 0.75 2022-03-31 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748472433-C3WO0MQFG4GSWW1QMTDD/FRAN.jpg Leadership (Copy) https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748472388-79NVE2HRNWR9AAYT8OJQ/MATTHEW.jpg Leadership (Copy) https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748472401-M0K7DEXPHIG16OMBW1V2/JoeV3.jpg Leadership (Copy) https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748472423-MD7BB9W417CDT4X6P08N/BROOKE.jpg Leadership (Copy) https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748472412-22Z43PECLVSHRQXHF86P/TYLER.jpg Leadership (Copy) https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748472376-G447OX6LQ81EPEP8IT10/image-asset.jpeg Leadership (Copy) https://promontorytx.com/careers daily 0.75 2022-04-28 https://promontorytx.com/leadership daily 0.75 2025-05-19 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748479093-VBWWDCO48RELD2XIJKU9/MATTHEW.jpg Leadership https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748479104-L6WXFX0R963524F5W6HC/TYLER.jpg Leadership https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1653311487685-8HMGOJOAOIWWNVE1OU3L/JoeV3.jpeg Leadership https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1653311655777-J4VSRUGXJF1Y2OJ7VVNL/JOHAN+%281%29+%281%29.jpg Leadership https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/e6012291-3cf9-4047-a722-96690bd6c870/Robert+Fallon+Portrait.jpg Leadership https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/6114721d-e405-43a5-acc8-1596fad3568b/_DLB8000-Edit.jpg Leadership https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/d416c2ab-ca87-48a6-8399-5b856f718dc1/Headshot_AC.jpeg Leadership https://promontorytx.com/our-story daily 0.75 2025-05-19 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748482042-5BA1IPP8C3B92DGYHO6K/nyc.jpg Our Story - A notable history. Promontory Therapeutics was founded by two entrepreneurs in New York City around a discovery-stage university license. Since that time, we have built inter-disciplinary teams — both internally and externally — and conducted collaborations globally. We are an independent and privately funded company, and hold the exclusive global license to a novel family of compounds that includes our lead agent, PT-112. Our Research and Development efforts comprise university and pharmaceutical industry collaborators in the US and Europe; along with development stage manufacturing in both the US and Europe. We have completed Phase 2 development of PT-112 in metastatic castration-resistant prostate cancer (mCRPC), including an End of Phase 2 (EOP2) meeting with U.S. FDA. Under a formal Collaborative Research and Development Agreement with the National Cancer Institute (NCI), PT-112 is under Phase 2 investigation for treatment of thymoma at NCI. We have received Orphan Drug designation for Thymoma and Multiple Myeloma. https://promontorytx.com/scientific-overview daily 0.75 2025-05-19 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1747670074455-C8AZWNXYHBVWLEGZ8JGF/Confidential_Promontory%2BTx_PT-112%2BProgram_Ipsen_13%2BMay%2B2025_vF-rev.jpg Scientific Overview https://promontorytx.com/pt-112 daily 0.75 2025-05-19 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/8c39f2a2-edc3-41a8-87cf-b56de1e63bab/Artboard+1+copy+6%402x.png About PT-112 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/168baa56-0421-4d4f-882a-7001f33f61c5/Artboard+1+copy+7%402x.png About PT-112 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/28807097-cd88-48ed-9e43-3e094abc8747/Artboard+1+copy+5%402x.png About PT-112 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/045f770b-8114-4063-a925-4409d46a5714/Artboard+1+copy+4%402x.png About PT-112 https://promontorytx.com/key-milestones-1 daily 0.75 2023-06-26 https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466897-U4KZKRMXAEUTYPIMS2PU/FDA.png Key Milestones (Copy) - 2017 PT-112 received FDA Orphan Drug Designation for use in relapsed or refractory multiple myeloma. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466906-SEMUPXHY14HFXKOM4PJQ/esmo2019.jpg Key Milestones (Copy) - 2019 Promontory gathered industry experts during the European Society of Medical Oncology Annual Congress to review clinical data from Phase I studies of PT-112 and to explore clinical development pathways. Promontory also presented at BIO CEO. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466860-BV0FCMGGJ36KO7EO8LJF/ohio-university.jpg Key Milestones (Copy) - 2010 Promontory Therapeutics was founded (under the name Phosplatin Therapeutics) concomitantly with its license transaction with Ohio University for a family of compounds that could be developed into anti-cancer agents. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466911-NQFNR3IL8346HLKP4H2L/IMG_6996.jpg Key Milestones (Copy) - 2020 Positive data from two phase I studies in metastatic castrate-resistant prostate cancer patients were presented at the American Society of Cancer Oncology’s Genitourinary (ASCO GU) Cancers Symposium. Promontory also announced the publication in OncoImmunology of in vitro and in vivo data demonstrating PT-112’s bona fide induction of immunogenic cell death (ICD) and its synergistic combination with immune checkpoint inhibitors. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/ca5072fd-b086-4f17-9bda-c4ddc0d4a6e2/Biotech+Breakthrough+2022-Promontory.png Key Milestones (Copy) - 2022 Promontory Therapeutics received the 2022 “Cancer Immunology Solution of the Year” award in the second annual BioTech Breakthrough Awards program. The Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466873-QD2PVE20VKF1TTCIUWZZ/gettyimages-1212821220-170667a.jpg Key Milestones (Copy) - 2014 Promontory launched its First-in-Human Phase I Clinical Trial of PT-112 in Solid Tumors. https://images.squarespace-cdn.com/content/v1/6245e7a23c39fa17cbca9b63/1648748466902-2IT1FWU783Q3582SPIW9/Ro+%26+Matthew+ESMO+Best+Poster.jpg Key Milestones (Copy) - 2018 PT-112 received FDA Orphan Drug Designation for use in thymoma and thymic carcinoma. The PT-112-101 Phase I study team was awarded with “Best Poster” honors across the full Developmental Therapeutics category at the European Society of Medical Oncology Annual Congress in Munich, Germany. https://promontorytx.com/publications daily 0.75 2025-10-24